186 related articles for article (PubMed ID: 30310134)
21. Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience.
Karimi M; Zarei T; Bahmanimehr A; Aramesh A; Daryanoush S; Haghpanah S
Ann Hematol; 2021 Dec; 100(12):2901-2907. PubMed ID: 34383102
[TBL] [Abstract][Full Text] [Related]
22. Hydroxyurea therapy in 49 patients with major beta-thalassemia.
Zamani F; Shakeri R; Eslami SM; Razavi SM; Basi A
Arch Iran Med; 2009 May; 12(3):295-7. PubMed ID: 19400608
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.
Elalfy MS; Adly AA; Ismail EA; Elhenawy YI; Elghamry IR
Eur J Haematol; 2013 Dec; 91(6):522-33. PubMed ID: 23927461
[TBL] [Abstract][Full Text] [Related]
24. Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the
Ghosh D; Panja A; Saha D; Banerjee U; Datta AK; Basu A
Genet Test Mol Biomarkers; 2021 Aug; 25(8):563-570. PubMed ID: 34406845
[No Abstract] [Full Text] [Related]
25. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
26. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.
Bradai M; Abad MT; Pissard S; Lamraoui F; Skopinski L; de Montalembert M
Blood; 2003 Aug; 102(4):1529-30. PubMed ID: 12702505
[TBL] [Abstract][Full Text] [Related]
27. Association of Exon 14 of the
Mohammadi Z; Mohammadi R; Haghpanah S; Moghadam M; Pazhoomand R; Karimi M
Hemoglobin; 2020 Nov; 44(6):406-410. PubMed ID: 33164584
[TBL] [Abstract][Full Text] [Related]
28. The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.
Banan M; Bayat H; Azarkeivan A; Mohammadparast S; Kamali K; Farashi S; Bayat N; Khani MH; Neishabury M; Najmabadi H
Hemoglobin; 2012; 36(4):371-80. PubMed ID: 22686296
[TBL] [Abstract][Full Text] [Related]
29. Hydroxyurea for lifelong transfusion-dependent β-thalassemia: A meta-analysis.
Algiraigri AH; Wright NAM; Paolucci EO; Kassam A
Pediatr Hematol Oncol; 2017 Nov; 34(8):435-448. PubMed ID: 29337597
[TBL] [Abstract][Full Text] [Related]
30. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
[TBL] [Abstract][Full Text] [Related]
31. Hydroxyurea in thalassemia intermedia--a promising therapy.
Dixit A; Chatterjee TC; Mishra P; Choudhry DR; Mahapatra M; Tyagi S; Kabra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
[TBL] [Abstract][Full Text] [Related]
32. Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis.
Algiraigri AH; Wright NAM; Paolucci EO; Kassam A
Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):116-125. PubMed ID: 28408107
[TBL] [Abstract][Full Text] [Related]
33. Hydroxyurea therapy in thalassemia.
Loukopoulos D; Voskaridou E; Stamoulakatou A; Papassotiriou Y; Kalotychou V; Loutradi A; Cozma G; Tsiarta H; Pavlides N
Ann N Y Acad Sci; 1998 Jun; 850():120-8. PubMed ID: 9668534
[TBL] [Abstract][Full Text] [Related]
34. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
[TBL] [Abstract][Full Text] [Related]
35. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
Musallam KM; Taher AT; Cappellini MD; Sankaran VG
Blood; 2013 Mar; 121(12):2199-212; quiz 2372. PubMed ID: 23315167
[TBL] [Abstract][Full Text] [Related]
36. Response to hydroxyurea therapy in beta-thalassemia.
Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
[TBL] [Abstract][Full Text] [Related]
37. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
[TBL] [Abstract][Full Text] [Related]
38. Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from Eastern India.
Bohara VV; Ray S; Chakrabarti P; Ray SS; Nath UK; Chaudhuri U
Hemoglobin; 2014; 38(1):44-8. PubMed ID: 24144212
[TBL] [Abstract][Full Text] [Related]
39. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
40. Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea.
Chondrou V; Stavrou EF; Markopoulos G; Kouraklis-Symeonidis A; Fotopoulos V; Symeonidis A; Vlachaki E; Chalkia P; Patrinos GP; Papachatzopoulou A; Sgourou A
Hum Genomics; 2018 Oct; 12(1):45. PubMed ID: 30285874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
